Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO (tedizolid phosphate) in the U.S.

Nachrichtenquelle: globenewswire
15.07.2020, 22:01  |  270   |   |   
  • Accretive transaction creates synergies and scale that strengthen Nabriva’s community-focused commercialization organization to optimize product uptake
     
  • Nabriva partners with Amplity Health to provide community-focused customer engagement and sales initiatives for SIVEXTRO and XENLETA (lefamulin)

DUBLIN, Ireland and KING OF PRUSSIA, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO (tedizolid phosphate) in the United States and certain of its territories. SIVEXTRO is an oxazolidinone-class antibacterial indicated in adults and pediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible Gram-positive microorganisms.

Ted Schroeder, Chief Executive Officer of Nabriva, commented, “We are excited to be selected by Merck & Co. Inc., Kenilworth, N.J., USA as their exclusive commercialization and distribution partner for SIVEXTRO in the U.S.  This transaction is aligned with our corporate strategy to add revenue generating products to our business that benefit patients and create value for shareholders. SIVEXTRO is an excellent fit in our portfolio, with a highly complementary customer base, creating synergies and scale with our commercial team.”

Patrick Magri, Merck & Co. Inc., Kenilworth, N.J., USA’s Senior Vice President, Hospital & Specialty Business stated, “For more than 80 years, Merck has contributed to the discovery and development of novel medicines to combat infectious diseases, and we continue that commitment today by driving innovation in the antibacterial marketplace. We are pleased to enter into this arrangement which provides Nabriva with the rights to market, sell and distribute SIVEXTRO in the United States.”  

Under the terms of the agreement, Nabriva will procure SIVEXTRO from Merck & Co. Inc., Kenilworth, N.J., USA and be responsible for marketing, sales, and distribution of SIVEXTRO in the U.S. through December 31, 2023, with renewable three-year extensions.

Additionally, Nabriva has engaged Amplity Health, a leading pharmaceutical contract commercial organization, to provide community-based commercial and sales services for SIVEXTRO and XENLETA in the U.S.

Seite 1 von 5
Nabriva Therapeutics (Spons. ADR) Aktie jetzt ab 0€ handeln - auf Smartbroker.de

Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel